Альтернативы поиска:
revolves. » evolves. (Расширить поиск), resolves. (Расширить поиск), evolved. (Расширить поиск)
resolvessssds. » resolvedssssds. (Расширить поиск)
resolve. » resolved. (Расширить поиск)
revolves. » evolves. (Расширить поиск), resolves. (Расширить поиск), evolved. (Расширить поиск)
resolvessssds. » resolvedssssds. (Расширить поиск)
resolve. » resolved. (Расширить поиск)
-
221
-
222
-
223
The alternative model 3.0.1 with reduced catalytic activity and <i>K</i><sub><i>M</i></sub> values in μM range.
Опубликовано 2025Предметы: -
224
-
225
-
226
The null catalytic main model 3.1 with <i>K</i><sub><i>M</i></sub> values in μM range.
Опубликовано 2025Предметы: -
227
-
228
-
229
-
230
-
231
-
232
The null catalytic main model 3.2 and <i>K</i><sub><i>M</i></sub> values in 0.1 μM range.
Опубликовано 2025Предметы: -
233
-
234
Stabilized host-parasite-hyperparasite cycle with <i>K</i><sub><i>M</i></sub> in 0.1 μM range.
Опубликовано 2025Предметы: -
235
Trialblazers: “Build-a-Trial” workshops for people with psoriatic arthritis
Опубликовано 2024“...This was to be followed in June 2024 by an application to the Medical Research Council (MRC) funding stream for a grant in understanding public involvement in non-clinical research.</p><p dir="ltr">In collaboration with the NDORMS’ public-involvement group, Open Arms, and led by clinician researcher Laura Coates, the team developed and ran Build-a-Trial workshops with patients to design this much needed trial from scratch. ...”
-
236
-
237
-
238
-
239
Results for each experimental case (as numbered in Fig 3 with their respective color).
Опубликовано 2022Предметы: -
240